Paying moms for app reviews: ethical or not?

Share this article:
An Abbott iPhone app is drawing attention to the practice of compensating bloggers for app reviews, as some call into question the ethics of pay-for-play PR.
Missy Berggren, whose Marketing Mama blog is prominent in Minnesota's parenting blogosphere, broke the story with a post which discussed Abbott's Similac StrongMoms Baby Journal iPhone App. Berggren argued that the app slyly preys on parents' fears to privilege formula over breastfeeding.
Blogged Berggren: “You know what else is concerning? The way Similac is marketing the app. I found out about it because a number of parenting bloggers are writing reviews of it. Paid reviews. The first two I read were by moms who had breastfed previously. I counted at least 10 blogger reviews by searching on Google for ‘Similac phone app.'”
All, she noted, were followed by the disclosure: “Note: I was compensated for my time in writing this post by Collective Bias. However, all opinions are honest and my own.” Collective Bias is a Bentonville, AR-based “social shopper marketing company.”
BNET blogger Jim Edwards spotted a similar grassroots effort for Novartis's WheresFlu app for Theraflu. Edwards didn't think much of the app, but found a bevy of posts extolling the virtues of the app, each followed by the disclaimer: “This is a sponsored post through the MomTrends Blogger Outreach Program for WheresFlu.”
Collective Bias declined to comment “for reasons of client confidentiality,” even to discuss their business model. MomTrends did not return reporter emails.
Berggren told MM&M the issue is an emotional one for many bloggers. “There are many bloggers who work from home, and this is how they put food on the table,” said Berggren, who heads brand management for a Minnesota hospital system when she's not blogging. “They feel that they're offering their unbiased views, that there should not be any question that the company should compensate us for our time and that there's nothing unethical about that.”
The posts appear to be in line with FTC guidance concerning the use of endorsements and testimonials. Under revised FTC guidelines issued in late 2009, any connection between the endorser and the seller of a product “that might materially affect the weight or credibility of the endorsement” must be “clearly and conspicuously” disclosed. The guidance specifically said bloggers must issue prominent disclosures and manufacturers must advise them of their responsibility to do so.
Berggren is a member of the BlogHer Network, which claims to reach 20.5 million unique users a month. BlogHer bloggers can opt in to hear about advertising opportunities or, through the company's review program, receive email pitches that may offer compensation ranging anywhere from $5 to $150. “Nobody ever says you have to talk nicely about it,” she said.
These budding social media marketing networks are arguably making the blogosphere more transparent. Abbott told Pharmalot's Ed Silverman that it used Collective Bias in part to ensure disclosure.
Berggren's beef with the app isn't about the compensated posts, but rather with the way she sees the app subtly undermining new mothers' confidence in breastfeeding to sell formula. “I think the story is the fact that a formula company is targeting breastfeeding moms through an app,” she said. “That's the part that feels shady to me.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?